Convert tumor lesions into a cancer vaccine to enhance immunotherapy. Build a multi-modality cancer immunotherapy platform.

Teclison Corporation is a clinical-stage biotechnology company dedicated to development of new cancer therapeutics. Teclison’s pipeline products (TATE and THIANA) were designed to have dual purposes, to induce tumor debulking by necrosis, and to use necrotic tumor as an in situ cancer vaccine to enhance anti-tumor immunity. Clinical evidence showed that TATE can reverse the resistance to anti-PD-(L)1 immune checkpoint inhibitors in immunotherapy-refractory patients and increase the chance of long-term survival. The technology also enables the future development of immune cell therapy and AI cancer vaccine, and combined into a multi-modality immunotherapy platform. Eventually we aim to replace conventional chemotherapy, and save patients from suffering with chemotherapy.

Teclison is conducting phase 2 clinical trials for TATE plus anti-PD-1 in U.S.A. and Taiwan, and has observed several advanced cancer patients achieving long-term survival in the trials. Some advanced cancer patients showed dramatic response after TATE plus anti-PD-1 treatment even they had failed immunotherapy before enrollment, a solid proof that Teclison’s strategy is synergistic with immunotherapy. We aim to advance TATE to a phase 3 registration study in 2025 and start licensing negotiation with global pharmaceutical companies.

Teclison was incorporated in 2013 by the founder Dr. Ray Lee, who is a M.D. from National Taiwan University and Ph.D. from Duke University. He was a faculty and physician scientist in U.S. academic centers, and an industrial leader in Merck and Roche Pharmaceutical for years before Teclison. The company is in the process of raising series B funding and planning IPO before Q1, 2025.

For more information, please refer to Teclison | Transforming cancer treatment by enhancing immunotherapy